Health Journal Online

Tag: Promise

  • Doctor Promotes Vasectomies With Promise to ‘Trip Out’ While High on Laughing Gas. Women Are Outraged

    Doctor Promotes Vasectomies With Promise to ‘Trip Out’ While High on Laughing Gas. Women Are Outraged

    An Idaho urologist’s viral TikTok marketing a vasectomy procedure that includes “tripping out” on pain medication while wearing virtual reality goggles has women asking why no one has made their reproductive healthcare experience more enticing.

    Dr. Austen Slade’s video, touted as “genius marketing” by men in the comments, makes having a vasectomy look fun.

    “Do you wanna have a legal excuse to trip out to some virtual reality content while high on nitrous oxide?” he asks viewers. “See me for your vasectomy and sign up for the ultimate relaxation package.”



    While praise rolled in for the innovative and patient-centered approach to a typically minor outpatient procedure, the comment section became a forum for women expressing long-standing frustration over pain management disparities in reproductive healthcare.

    Responses ranged from disbelief to anger. Dozens of women reported being offered only ibuprofen—or nothing at all—for procedures described as excruciating.

    “Damn, I passed out and threw up when I got my IUD and went back to work after,” one wrote.

    “Dang when we get IUDs we get ibuprofen and denied PTO requests 😪,” said another.

    Some women shared harrowing experiences of undergoing intrauterine device (IUD) insertions, cervical biopsies, and even abdominal surgeries with minimal or no pain relief.

    One user, @momo_vs_endo, recalled a gynecologist brushing off her pain during an IUD placement despite her crying. “She grabbed my shoulders and looked me in the eyes to say ‘You’re going to be fine,’ then walked out.”

    Another, @Introvertebrate32, described withstanding an unanesthetized cervical biopsy as she battled cancer: “No numbing, no pain management at all while I cried and almost loss consciousness due to the extreme pain.”

    “They make women endure colposcopies, uterine biopsies, and IUD placement with ZERO pain management and offer this to men for something they get completely numbed for?!” a woman said. “They wouldn’t even let my husband stay and hold my hand for my biopsy!!”

    A mother of five completely rejected the concept of cushioning the vasectomy experience, admitting: “Had I known this was an option prior to my husband getting his vasectomy I would have made sure he never found out about it.”

    But most women just wanted the same consideration. “I’m happy for them, but this made me irrationally ANGRY with what women have to go through,” one wrote, with another quipping, “PLEASE put this on my OBGYN’s FYP (for you page) not mine LMAO.”

    Dr. Slade weighed in on the tide of outrage from female patients, writing, “That just isn’t right,” in reply to one woman who noted the disparity in pain management.

    He also responded to a user who questioned why he wasn’t “liking” many comments from women. “Feels weird liking stories about being poorly treated,” Slade wrote. “I’ve let several gynecologists know about the comments I’m receiving.”

    The 11 second TikTok achieved its desired effect — the video racked up nearly one million views, got a lot of laughs, and had dozens of commenters announcing their willingness to book the procedure. It also unintentionally sparked conversation about inequity in pain management and calls for a reassessment of how healthcare systems approach procedures for women.

    As one commenter summed up: “Like. Yes. This is good. But also do this for women. Hear that OBGYNs???”

    Originally published on Latin Times

    Source link

  • New drug shows promise in clearing HIV from brain

    New drug shows promise in clearing HIV from brain

    An experimental drug originally developed to treat cancer may help clear HIV from infected cells in the brain, according to a new Tulane University study.

    For the first time, researchers at Tulane National Primate Research Center found that a cancer drug significantly reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain by targeting and depleting certain immune cells that harbor the virus.

    Published in the journal Brain, this discovery marks a significant step toward eliminating HIV from hard-to-reach reservoirs where the virus evades otherwise effective treatment.

    “This research is an important step in tackling brain-related issues caused by HIV, which still affect people even when they are on effective HIV medication,” said lead study author Woong-Ki Kim, PhD, associate director for research at Tulane National Primate Research Center. “By specifically targeting the infected cells in the brain, we may be able to clear the virus from these hidden areas, which has been a major challenge in HIV treatment.”

    Antiretroviral therapy (ART) is an essential component of successful HIV treatment, maintaining the virus at undetectable levels in the blood and transforming HIV from a terminal illness into a manageable condition. However, ART does not completely eradicate HIV, necessitating lifelong treatment. The virus persists in “viral reservoirs” in the brain, liver, and lymph nodes, where it remains out of reach of ART.

    The brain has been a particularly challenging area for treatment due to the blood-brain barrier — a protective membrane that shields it from harmful substances but also blocks treatments, allowing the virus to persist. In addition, cells in the brain known as macrophages are extremely long-lived, making them difficult to eradicate once they become infected.

    Infection of macrophages is thought to contribute to neurocognitive dysfunction, experienced by nearly half of those living with HIV. Eradicating the virus from the brain is critical for comprehensive HIV treatment and could significantly improve the quality of life for those with HIV-related neurocognitive problems.

    Researchers focused on macrophages, a type of white blood cell that harbors HIV in the brain. By using a small molecule inhibitor to block a receptor that increases in HIV-infected macrophages, the team successfully reduced the viral load in the brain. This approach essentially cleared the virus from brain tissue, providing a potential new treatment avenue for HIV.

    The small molecule inhibitor used, BLZ945, has previously been studied for therapeutic use in amyotrophic lateral sclerosis (ALS) and brain cancer, but never before in the context of clearing HIV from the brain.

    The study, which took place at the Tulane National Primate Research Center, utilized three groups to model human HIV infection and treatment: an untreated control group, and two groups treated with either a low or high dose of the small molecule inhibitor for 30 days. The high-dose treatment lead to a notable reduction in cells expressing HIV receptor sites, as well as a 95-99% decrease in viral DNA loads in the brain .

    In addition to reducing viral loads, the treatment did not significantly impact microglia, the brain’s resident immune cells, which are essential for maintaining a healthy neuroimmune environment. It also did not show signs of liver toxicity at the doses tested.

    The next step for the research team is to test this therapy in conjunction with ART to assess its efficacy in a combined treatment approach. This could pave the way for more comprehensive strategies to eradicate HIV from the body entirely.

    This research was funded by the National Institutes of Health, including grants from the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, and was supported with resources from the Tulane National Primate Research Center base grant of the National Institutes of Health, P51 OD011104.

    Source link

  • New gene therapy approach shows promise for Duchenne muscular dystrophy

    New gene therapy approach shows promise for Duchenne muscular dystrophy

    Indiana University School of Medicine researchers have made a significant breakthrough in developing a new gene therapy approach that restores full-length dystrophin protein, which could lead to new treatments for people with Duchenne muscular dystrophy (DMD).

    The study, recently published in Nature Communications, demonstrates the effectiveness of their novel gene therapy technology in improving muscle tissue and overall strength in mice models with Duchenne muscular dystrophy.

    Duchenne muscular dystrophy is a genetic disorder caused by mutations in the DMD gene, resulting in a lack of the protein dystrophin. This deficiency leads to progressive muscle weakness and loss of muscle tissue over time. Patients with the disease experience impaired mobility, heart and lung problems, and ultimately a shortened life expectancy.

    “Current gene therapy for Duchenne muscular dystrophy utilizes a truncated version of dystrophin,” said Renzhi Han, PhD, senior author of the study and professor of pediatrics at the IU School of Medicine. “Unfortunately, this option doesn’t fully protect the muscles because it lacks many important functional domains of full-length dystrophin.”

    While the U.S. Food and Drug Administration recently approved a micro-dystrophin gene therapy for Duchenne muscular dystrophy, Han said the therapeutic outcomes have been less satisfactory than expected.

    Building on their experience using adeno-associated virus methods to deliver extra-large therapeutic genes into cells, Han and his team at the Herman B Wells Center for Pediatric Research developed a triple-adeno-associated virus vector system to deliver a complete version of the dystrophin protein into the muscles.

    “We optimized and tested our new three-vector system to make sure it produced and assembled the full-length dystrophin protein effectively,” Han said. “Our data confirmed we successfully restored full-length dystrophin in both the skeletal and heart muscles of mice with DMD, leading to significant improvements in their muscle health, strength and function.”

    Han has filed a provisional patent application for his triple-adeno-associated virus vector system and is collaborating with the IU Innovation and Commercialization Office to advance the treatment toward market availability. He is also seeking additional funding so patients with Duchenne muscular dystrophy have access to promising new treatment options.

    “I believe this new gene therapy approach offers significant advantages to patients compared to what they currently have available, and I’m eager to get it into further clinical development,” he said.

    Other IU School of Medicine study authors include Yuan Zhou, Chen Zhang, Weidong Xiao and Roland W. Herzog.

    Source link